Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SELL | P14151 | 1/20 | 0.36 |
| ▸ | SELP | P16109 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28896783 | 0.84 | SELL (0.48) | GABRA1GABRB2MAPK1MEN1KMT2A | |
| SCHEMBL20145965 | 0.84 | HMGB1 (0.37) | SLC22A6SLC22A8GRM1KDM4EHSD17B10 | |
| SCHEMBL28844937 | 0.83 | KDM4E (0.37) | GABRA1GABRB2MAPK1MEN1KMT2A | |
| SCHEMBL8895803 | 0.83 | KDM4E (0.43) | MAPK1MEN1KMT2AGAASLC22A6 | |
| SCHEMBL2428559 | 0.83 | MAPK1 (0.44) | GABRA1GABRB2MAPK1MEN1KMT2A | |
| SCHEMBL299374 | 0.78 | SELL (0.41) | GABRA1GABRB2GAAKDM4EHSD17B10 | |
| SCHEMBL8816524 | 0.78 | SELL (0.41) | GABRA1GABRB2MAPK1KDM4EHSD17B10 | |
| SCHEMBL8772614 | 0.78 | SLC22A6 (0.44) | GABRA1GABRB2MEN1KMT2AGAA | |
| SCHEMBL7369721 | 0.78 | MRGPRX4 (0.45) | GABRA1GABRB2KMT2AKDM4EHSD17B10 | |
| SCHEMBL16035208 | 0.77 | KDM4E (0.44) | MAPK1MEN1KMT2AELANEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851119-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851119-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2020-05-21 | — | — | US | disclosed |
| US-10464951-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464951-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2019-11-05 | — | — | US | disclosed |
| EP-2970106-B1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2970106-B1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2018-03-22 | — | — | US | disclosed |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-9127024-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-9127024-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-9127024-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| WO-2014144380-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORPORATION (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION | 2014-09-18 | — | — | US | disclosed |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION | 2014-09-18 | — | — | US | disclosed |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464951-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | GABRA1 2095/4885GABRB2 1930/4885MAPK1 1876/4885 |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | GABRA1 2095/4885GABRB2 1930/4885MAPK1 1876/4885 |
| US-10851119-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | GABRA1 2095/4885GABRB2 1930/4885MAPK1 1876/4885 |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | CD22, BRDT, BCR | GABRA1 2095/4885GABRB2 1930/4885MAPK1 1876/4885 |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | GABRA1 2095/4885GABRB2 1930/4885MAPK1 1876/4885 |
| US-20180079759-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | GABRA1 2095/4885GABRB2 1930/4885MAPK1 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.